JCSM Rapid Communications (Jul 2022)

The impact of cachexia on dietary intakes, symptoms, and quality of life in advanced cancer

  • Koji Amano,
  • Vickie E. Baracos,
  • Tatsuya Morita,
  • Tomofumi Miura,
  • Naoharu Mori,
  • Ryohei Tatara,
  • Takaomi Kessoku,
  • Akihiro Tokoro,
  • Keita Tagami,
  • Hiroyuki Otani,
  • Masanori Mori,
  • Tomohiko Taniyama,
  • Nobuhisa Nakajima,
  • Erika Nakanishi,
  • Jun Kako,
  • Daisuke Kiuchi,
  • Hiroto Ishiki,
  • Hiromichi Matsuoka,
  • Eriko Satomi,
  • Mitsunori Miyashita

DOI
https://doi.org/10.1002/rco2.61
Journal volume & issue
Vol. 5, no. 2
pp. 162 – 170

Abstract

Read online

Abstract Background The relationships between cachexia stages and the Functional Assessment of Anorexia/Cachexia Therapy Anorexia Cachexia Subscale (FAACT ACS) 12‐item, 5‐item anorexia symptoms, and 4‐item anorexia concerns have not been investigated in Asian patients with advanced cancer. Methods This is a multicentre questionnaire survey conducted in palliative and supportive care settings across Japan. Consecutive patients were enrolled. Patient characteristics and anthropometric measurements were obtained. Dietary intakes and nutrition impact symptoms were also assessed. Patients evaluated their quality of life (QOL) using FAACT ACS. Subjects were divided into two groups, that is, pre‐cachexia (non‐cachexia) and cachexia and refractory cachexia (cachexia), based on cancer cachexia criteria from the international consensus. Comparisons were performed using the Mann–Whitney U test or chi‐squared test. To evaluate the relationship between cachexia stages and FAACT ACS 12‐item, 5‐item anorexia symptoms, and 4‐item anorexia concerns, adjusted odd ratios (ORs) and 95% confidence intervals (CIs) were calculated in the logistic models. Results Among 495 patients, 378 (76.4%) responded. Due to missing data, 344 patients were classified into the non‐cachexia group (n = 174) and cachexia group (n = 170), and 318 remained in the analysis of FAACT ACS. The cachexia group had a more impaired performance status, a lower body mass index, and a higher frequency of weight loss in 1 month (P = 0.021, <0.001, and <0.001, respectively). Advancing stages were associated with lack of appetite and reduced dietary intakes (P < 0.001 and P < 0.001, respectively). QOL scores were significantly worse in the cachexia group in FAACT ACS 12‐item, 5‐item anorexia symptoms, and 4‐item anorexia concerns (P < 0.001, P = 0.001, and P < 0.001, respectively). In the models of FAACT ACS 12‐item, 5‐item anorexia symptoms, and 4‐item anorexia concerns, significantly higher adjusted ORs than in the non‐cachexia group were observed in the cachexia group [2.24 (95% CI 1.34–3.77), P = 0.002; 1.77 (95% CI 1.08–2.92), P = 0.024; and 2.18 (95% CI 1.29–3.70), P = 0.004, respectively]. Conclusions FAACT ACS 12‐item, 5‐item anorexia symptoms, and 4‐item anorexia concerns are useful for identifying patients at risk of QOL that deteriorates with advancing stages in this population.

Keywords